Temporary suspension of Inventiva shares on Euronext Paris

Inventiva, a biopharmaceutical company, announced the temporary suspension of trading in its ordinary shares on Euronext Paris. This decision was made at the company's request in anticipation of a financing project, the details of which will be released at a later date. The suspension took effect at the market opening at 9:00 a.m. CEST.

Trading on Euronext Paris is scheduled to resume around 3:30 p.m. CEST that day, simultaneously with the Nasdaq Global Market where the company is listed under the symbol "IVA".

Inventiva focuses primarily on the treatment of metabolic steatohepatitis (MASH), a chronic liver disease. The company is currently conducting a pivotal phase 3 trial of lanifibranor, a pan-PPAR agonist, to evaluate its efficacy in patients with MASH.